Wren Laboratories

Moving forward! Cutting edge, state of the art biomarkers, that make a difference!

Thank you Vincent. Ad Astra!

??Revolutionizing Prostate Cancer Care with PROSTest! Wren Laboratories is leading the way in prostate cancer detection with PROSTest, AI-enhanced non-invasive liquid biopsy multigene mRNA expression test that offers better diagnostic accuracy, eliminates unnecessary biopsies, and enhances patient outcomes. PROSTest Key Highlights ? 96.0% sensitivity at 99.3% specificity, significantly outperforming traditional PSA testing (91.2% sensitivity, 65.8% specificity) ? 94% sensitivity for detecting minimal residual disease (MRD) and recurrence, compared to just 79% for Gallium-PET scans ? Only 1mL of blood required, making it a simple and less invasive alternative to traditional biopsy ? More accurate than PSA in detecting prostate cancer and monitoring therapeutic response ?? PROSTest offers a critical advantage: it eliminates unnecessary biopsies often triggered by elevated PSA levels of 3ng/mL or higher, which can frequently result in false positives. In fact, of the 1 million biopsies performed annually in the U.S. due to elevated PSA, only about 190,000 lead to a diagnosis of clinically significant prostate cancer. With PROSTest, you can get a much more accurate result, potentially avoiding the risks and discomfort of unnecessary biopsies. Now available under CLIA, CAP, and NYSDOH certifications, PROSTest is offered to both patients and investigators, ensuring more accurate, reliable, and timely prostate cancer diagnostics. Learn more about how PROSTest is revolutionizing prostate cancer care: www.wrenlaboratories.com Read the full publications at https://lnkd.in/gag2GSVY #WrenLaboratories #ProstateCancer #LiquidBiopsy #PrecisionMedicine #OncologyInnovation #PROSTest #ProstateCancerDetection #NonInvasive #BetterOutcomes #CLIA #CAP #NYSDOH

??Wren Laboratories Advances Precision Medicine for Neuroendocrine Tumors! Diagnosing and managing gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has long been a challenge. With the critical need for a reliable biomarker, Wren Laboratories has taken a major leap forward! Introducing NETest 2.0 – our AI-enhanced non-invasive liquid biopsy multigene mRNA expression test that significantly improves the detection and monitoring of NETs. ? >95% sensitivity for detecting NETs ? >90% accuracy in identifying progressive disease ? Enhanced ability to differentiate NETs from other malignancies ? Validated in global patient cohorts across the U.S., Europe, Latin America, Africa, and Asia ? Continues to offer the PPQ score, previously established in NETest 1.0, which predicts patient response to PRRT with a 98% positive predictive value (PPV) and 93% negative predictive value (NPV) Powered by machine learning and a refined 51-gene expression algorithm, NETest 2.0 delivers unmatched diagnostic and prognostic accuracy—a game-changer for clinicians and patients alike. Why does this matter? Earlier and more precise detection + prediction of response to therapeutics = better treatment and management decisions = improved patient outcomes. With proven effectiveness in diverse populations, NETest 2.0 is setting a new standard for NET diagnostics. ?? Now available under CLIA, CAP, and NYSDOH certifications, the test is being offered to patients and investigators, making cutting-edge NET diagnostics more accessible than ever. Proudly developed and validated by Wren Laboratories, this breakthrough underscores our commitment to revolutionizing precision oncology! ?? Read the full publication here: https://lnkd.in/ghyiCTEb #WrenLaboratories #NeuroendocrineTumors #LiquidBiopsy #ArtificialIntelligence #PrecisionMedicine #NETest #OncologyInnovation #PRRT #PPQScore #CLIA #CAP #NYSDOH

We just published data from a clinical validation study that confirms the high sensitivity (94%) and specificity (88%) of the novel #liquidbiopsy multigene expression assay PROSTest? in detecting #ProstateCancer in a diverse USA cohort. The assay's robustness and reproducibility (98.5-99.2%) support its potential as a reliable diagnostic tool for PCa detection and monitoring: https://hubs.la/Q033ZKwg0

Incredibly important!

The Team at Wren Laboratories is spreading awareness of Neuroendocrine Cancer by partnering with patients, providers, and the community to create a global voice for Neuroendocrine cancer! Neuroendocrine cancer is often misdiagnosed for a long time. Learn more about NETCancer and Wren Laboratories blood-based tests that utilize mRNA and AI at > https://hubs.la/Q02XPnjB0 #NETCancerDay2024 #NETestAdvances #DetectNETsEarly #EarlyNETDetection #NETest2.0 #NeuroendocrineCancerAwareness #EarlyCancerDetection #NETestSavesLives #NANETS #DetectNETsBeforeSymptoms #AdvancedNETDiagnostics #CatchNETsEarly

Dr. Srinivas Koduru Ph.D our Director of Transcriptomics is getting ready to present his findings in "Assessing Saliva for Cancer Biomarker Discovery: A Liquid Biopsy Approach" To learn how we are transforming cancer detection through mRNA biomarkers visit our website > https://hubs.la/Q02WNRBF0 #wrenlabs #liquidbiopsy #NETest2.0 #cancer #mRNA #earlydetection

Heading to NANETS in #chicago in a couple weeks? Stop by our table and learn how our NETest 2.0 is 94% accurate in detecting neuroendocrine tumors, offering unmatched reliability for early diagnosis. Discover why more healthcare providers are choosing NETest 2.0 for their patients > https://hubs.la/Q02WpSx60 #NETestAdvances #DetectNETsEarly #EarlyNETDetection #NETest2.0 #NeuroendocrineCancerAwareness #EarlyCancerDetection #NETestSavesLives #NANETS #DetectNETsBeforeSymptoms #AdvancedNETDiagnostics #CatchNETsEarly

A legend and a fighter!